High expression in the CD133+ compartment of genes such as LRRFIP1, transcriptional repressor of EGFR [49], would support the idea of EGFR gene as a secondary event in the process of GBM development by promoting infiltration and mediating resistance to therapy. This evidence concerns the gene EGFR and glioblastoma.